Cambridge Major Laboratories and AAIPharma Services Announce Merger
02 10월 2013 - 9:00PM
Business Wire
Cambridge Major Laboratories, Inc. (“CML”), a global leader in
pharmaceutical API development and manufacturing, and AAIPharma
Services Corp. (“AAIPharma”), a leading global provider of
pharmaceutical analytical testing, product development, and
manufacturing services, have announced their intent to merge to
form the premier global supplier of integrated CMC services.
Financial terms of the merger were not disclosed. The merger is
expected to close by the end of October 2013, subject to
Hart-Scott-Rodino approval and other closing conditions. “The basis
for the merger was to start with the right building blocks - a
merger of two equals: two highly respected, market-leading firms
with proven expertise in API development, analytical chemistry, and
finished dosage forms,” said Brian Scanlan, CEO & President of
CML. “We believe that we have a strong foundation to deliver
superior customer-oriented solutions to expedite drug development
and commercialization.”
Scanlan added, “Joining forces to offer a full suite of
integrated CMC services delivers meaningful value to customers and
the ability to execute with equal strength across API development,
analytical services, and finished dosage form manufacturing. The
combined CML and AAIPharma will provide a superior customer
experience defined by high-quality facilities, best-in-class
capabilities, scientific expertise, geographic proximity, and
effective support services that maximize scientific and project
interaction at each phase.”
”The merger of these two organizations will offer customers a
reliable partner that can address the majority of their
pharmaceutical development and manufacturing requirements,” stated
Patrick Walsh, CEO of AAIPharma Services. “The combined
organization will provide comprehensive services that include
process chemistry, solid state chemistry, API manufacturing,
formulation development, analytical development and testing
services, clinical and commercial finished dosage form
manufacturing (oral solid and sterile), packaging, and stability
services, all supported by robust project management.”
About Cambridge Major Laboratories, Inc.
Cambridge Major Laboratories, Inc. (CML) is a leading global
chemistry outsourcing partner to the pharmaceutical and
biotechnology industries. The Company produces pharmaceutical
intermediates and Active Pharmaceutical Ingredients (API), from
early preclinical development to commercial manufacturing.
Operating from FDA-inspected facilities in the US and Europe, CML
is organized along five key Centers of Excellence, including:
Process Chemistry, GMP Manufacturing, Solid State Chemistry,
Analytical Services, and Quality/Regulatory Compliance. CML is a
portfolio company of American Capital, Ltd. (NASDAQ: ACAS).
For more information on the company, visit www.c-mlabs.com
About AAIPharma Services Corp.
AAIPharma Services Corp. is a leading provider of contract
services that support all phases of drug development. The company’s
wide array of capabilities includes analytical and formulation
development, material testing services, microbiology, clinical and
commercial contract manufacturing, pharmaceutical packaging, and
stability services. Serving more than 600 clients around the globe
and headquartered in Wilmington, N.C., AAIPharma is a portfolio
company of Water Street Healthcare Partners, a strategic investor
focused exclusively on health care.
For more information on the company,
visit www.aaipharma.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131002005389/en/
Media Contacts:CMLKim Black-Washington,
1-262-955-4715k.black-washington@c-mlabs.comorAAIPharma Services
Corp.Jeff A. Parrott, Ph.D.,
1-800-575-4224media_relations@aaipharma.comRelated
Links:Cambridge Major Laboratories Home
Pagehttp://www.c-mlabs.com/AAIPharma Home
Pagehttp://www.aaipharma.com/
American Capital Strategies (NASDAQ:ACAS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
American Capital Strategies (NASDAQ:ACAS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024